Literature DB >> 19817755

Association between asthma control and bronchial hyperresponsiveness and airways inflammation: a cross-sectional study in daily practice.

V Quaedvlieg1, J Sele, M Henket, R Louis.   

Abstract

BACKGROUND: The primary end-point in the management of asthma is to obtain optimal control. The aim of this study was to assess the relationships between the markers of airway inflammation (sputum eosinophilia and exhaled nitric oxide), bronchial hyperresponsiveness (BHR) and asthma control.
METHODS: One hundred and thirty-four patients were recruited from our asthma clinic between January 2004 and September 2005 [mean age: 42 years, mean forced expiratory volume in 1 s (FEV(1)): 86% predicted]. Eighty-six of them were treated by inhaled corticosteroids, 99 were atopic and 23 were current smokers. They all underwent detailed investigations including fractional-exhaled nitric oxide (FE(NO)) measurement, sputum induction and methacholine challenge when FEV(1) was >70% predicted, and filled in a validated asthma control questionnaire (ACQ6 Juniper).
RESULTS: When dividing patients into the three groups according to their level of asthma control determined by ACQ [well-controlled asthma (ACQ score <or=0.75), borderline (0.75<ACQ score <1.5) and uncontrolled asthma (ACQ score >or=1.5)], it appeared that uncontrolled asthmatics had a greater BHR to methacholine and sputum eosinophilia than controlled asthma (P<0.05, P<0.001, respectively). By contrast, we failed to show significant differences in the FE(NO) levels between the groups. With receiver-operating characteristic curves for differentiating uncontrolled (ACQ>or=1.5) from controlled and borderline (ACQ<1.5) asthma, sputum eosinophilia and methacholine responsiveness were found to be more accurate than FE(NO) (area under the curve: 0.72, 0.72 and 0.59, respectively).
CONCLUSION: In a broad spectrum of asthmatics encountered in clinical practice, sputum eosinophilia and methacholine bronchial hyperresponsiveness, but not FE(NO), are associated with uncontrolled asthma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19817755     DOI: 10.1111/j.1365-2222.2009.03332.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  10 in total

Review 1.  Developments in the field of allergy in 2009 through the eyes of Clinical and Experimental Allergy.

Authors:  H W Chu; C M Lloyd; W Karmaus; P Maestrelli; P Mason; G Salcedo; J Thaikoottathil; A J Wardlaw
Journal:  Clin Exp Allergy       Date:  2010-11       Impact factor: 5.018

2.  Pituitary adenylate cyclase-activating peptide receptor 1 mediates anti-inflammatory effects in allergic airway inflammation in mice.

Authors:  H D Lauenstein; D Quarcoo; L Plappert; C Schleh; M Nassimi; C Pilzner; S Rochlitzer; P Brabet; T Welte; H G Hoymann; N Krug; M Müller; E A Lerner; A Braun; D A Groneberg
Journal:  Clin Exp Allergy       Date:  2010-11-09       Impact factor: 5.018

3.  Comparison of orally exhaled nitric oxide in allergic versus nonallergic rhinitis.

Authors:  A Fusun Kalpaklioglu; Ilkay K Kalkan
Journal:  Am J Rhinol Allergy       Date:  2012 Mar-Apr       Impact factor: 2.467

Review 4.  2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.

Authors:  Michelle M Cloutier; Alan P Baptist; Kathryn V Blake; Edward G Brooks; Tyra Bryant-Stephens; Emily DiMango; Anne E Dixon; Kurtis S Elward; Tina Hartert; Jerry A Krishnan; Robert F Lemanske; Daniel R Ouellette; Wilson D Pace; Michael Schatz; Neil S Skolnik; James W Stout; Stephen J Teach; Craig A Umscheid; Colin G Walsh
Journal:  J Allergy Clin Immunol       Date:  2020-12       Impact factor: 10.793

5.  Reduced sputum expression of interferon-stimulated genes in severe COPD.

Authors:  Clarissa Hilzendeger; Jane da Silva; Monique Henket; Florence Schleich; Jean Louis Corhay; Tatiana Kebadze; Michael R Edwards; Patrick Mallia; Sebastian L Johnston; Renaud Louis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-06-30

Review 6.  Biomarkers in the Management of Difficult Asthma.

Authors:  Florence Schleich; Sophie Demarche; Renaud Louis
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

7.  Does asthma control as assessed by the asthma control test reflect airway inflammation?

Authors:  Mine Bora; Aylin Ozgen Alpaydin; Arzu Yorgancioglu; Gizem Akkas; Aydın Isisag; Aysın Sakar Coskun; Pınar Celik
Journal:  Multidiscip Respir Med       Date:  2011-10-31

8.  Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation.

Authors:  Florence N Schleich; Maité Manise; Jocelyne Sele; Monique Henket; Laurence Seidel; Renaud Louis
Journal:  BMC Pulm Med       Date:  2013-02-26       Impact factor: 3.317

9.  Concordance for changes in allergic asthma domain variables after short-term corticosteroid therapy.

Authors:  Philip E Silkoff; Mark Sarno; Solomon Ssenyange; Vivek Balasubramanyam; Brian Awabdy; Ryan Leard
Journal:  BMC Pulm Med       Date:  2020-05-14       Impact factor: 3.317

Review 10.  An update on the diagnostic biomarkers for asthma.

Authors:  Rashmi Pandey; Ved Parkash; Surya Kant; Ajay K Verma; S N Sankhwar; Avinash Agrawal; Devendra Parmar; Sheetal Verma; Md Kaleem Ahmad
Journal:  J Family Med Prim Care       Date:  2021-04-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.